NEW YORK, Jan. 14, 2020 /PRNewswire/ -- Insilico
Medicine is pleased to announce that it has entered into a research
collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's
machine learning technology and proprietary Pandomics Discovery
Platform with the aim of identifying real-world evidence for
potential therapeutic targets implicated in a variety of
diseases.
"Insilico is advancing its latest target identification systems
utilizing machine learning, generative biology methods, and
synthetic data generation pipelines, and we are pleased to be
collaborating with Pfizer on its target identification efforts,"
said Alex Zhavoronkov, PhD, founder,
and CEO of Insilico Medicine.
"We look forward to working with Insilico as Pfizer continues to
explore new technologies that may be able to help us identify
targets and biomarkers that could assist in our discovery programs,
and potentially lead to breakthrough therapeutics for patients with
unmet medical needs," said Morten
Sogaard, Vice President, Target Sciences, Pfizer.
In September 2019, Insilico
Medicine announced a $37 million
round led by prominent biotechnology and AI investors.
About Insilico Medicine
Since 2014 Insilico Medicine
is focusing on generative models, reinforcement learning (RL), and
other modern machine learning techniques for the generation of new
molecular structures with the specified parameters, generation of
synthetic biological data, target identification, and prediction of
clinical trials outcomes. Recently, Insilico Medicine published
some of the results in Nature Biotechnology, and secured
$37 million in series B funding.
Since its inception, Insilico Medicine raised over $52 million, published over 70 peer-reviewed
papers, applied for over 20 patents, and received multiple industry
awards.
Website http://insilico.com/
Media Contact
For further information, images or
interviews, please contact:
ai@insilico.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/insilico-enters-into-research-collaboration-with-pfizer-inc-to-explore-novel-data-and-artificial-intelligence-system-for-potential-therapeutic-targets-300986562.html
SOURCE Insilico Medicine